Research Fellow
- About
-
- Email Address
- m.cruickshank@abdn.ac.uk
- Office Address
Health Services Research Unit
3rd Floor Health Sciences Building
Foresterhill
Aberdeen
AB25 2ZD- School/Department
- School of Medicine, Medical Sciences and Nutrition
Biography
Moira Cruickshank is a Research Fellow in the Evidence Synthesis programme of ACE.
Moira was a Police Officer in the Metropolitan Police before returing to full time education at the University of Aberdeen in 2002. She graduated with BSc (Hons) Psychology in 2006 and MRes Psychology in 2007. Moira then undertook a PhD in Psychology within HSRU (now ACE), supervised by Prof Jill Francis, Dr Rachael Powell and Prof James N'Dow. The PhD was funded by UCAN, a local charity aiming to improve the experience and outcomes of people diagnosed with urological cancer. Since completing her PhD in 2011, Moira has been a systematic reviewer within the Evidence Synthesis programme and is involved in technology assessment appraisals and health technology assessment reviews.
- Publications
-
Page 2 of 6 Results 11 to 20 of 52
Ivosidenib for treating advanced cholangiocarcinoma with an IDH1 R132 mutation after 1 or more systemic treatments
National Institute for Health and Care Excellence (NICE). 20 pagesBooks and Reports: Commissioned Reports- [ONLINE] https://www.nice.org.uk/guidance/ta948
- [ONLINE] Page 214-316
- [ONLINE] https://www.nice.org.uk/guidance/ta948/evidence
Netarsudil-latanoprost for previously treated openangle glaucoma or ocular hypertension [ID1363]: NICE Single Technology Appraisal
Commissioned by National Institute for Health and Care Excellence (NICE). Aberdeen HTA GroupBooks and Reports: Commissioned ReportsClinical Predictors Of Symptomatic Benefit In Men With Low Testosterone During Testosterone Treatment Compared With Placebo:: Results Of Individual Patient And Aggregate Data Meta-analyses
Annual Meeting of the Endocrine Society 2023, bvad114.1704Contributions to Journals: Abstracts- [ONLINE] DOI: https://doi.org/10.1210/jendso/bvad114.1704
Symptomatic benefits of testosterone treatment in patient subgroups: a systematic review, individual participant data meta-analysis, and aggregate data meta-analysis
The Lancet Healthy Longevity, vol. 4, no. 10, pp. e561-e572Contributions to Journals: ArticlesDeucravacitinib for treating moderate-to-severe plaque psoriasis
Evidence Review Group report in support of NICE STA Programme. London: National Institute for Health and Care Excellence. 155 pagesBooks and Reports: Commissioned ReportsSecukinumab for Moderate-to-Severe Hidradenitis Suppurativa [ID4039]: NICE Single Technology Appraisal
Commissioned by National Institute for Health and Care Excellence (NICE). Aberdeen HTA GroupBooks and Reports: Commissioned ReportsPMON260 Cost-Effectiveness of Testosterone Treatment for Men with Hypogonadism
Annual Meeting of the Endocrine Society 2022Contributions to Conferences: Posters- [ONLINE] DOI: https://doi.org/10.1210/jendso/bvac150.1447
PMON258 Patient-Reported Outcomes for men with Hypogonadism and the Impact of Low Testosterone Levels: a review of measures
Annual Meeting of the Endocrine Society 2022Contributions to Conferences: Posters- [ONLINE] DOI: https://doi.org/10.1210/jendso/bvac150.1445
Management of the first stage of convulsive status epilepticus in adults: a systematic review of current randomised evidence
Journal of Neurology, vol. 269, no. 7, pp. 3420-3429Contributions to Journals: Review articles- [ONLINE] DOI: https://doi.org/10.1007/s00415-022-10979-2
- [OPEN ACCESS] http://aura.abdn.ac.uk/bitstreams/37bb6e56-6464-46d4-9661-f1cacc32dc10/download
- [ONLINE] View publication in Scopus
Axicabtagene ciloleucel for treating relapsed or refractory diffuse large B-cell lymphoma after one systemic therapy
London: Evidence Review Group report in support of NICE STA Programme. London: National Institute for Health and Care Excellence. 128 pagesBooks and Reports: Commissioned Reports